Resverlogix recently participated in the symposium, Epigenetics: Cancer and Beyond, at the New York Academy of Sciences. An international assembly of biomedical investigators convened to explore the therapeutic potential of pharmacologic modulation of the epigenome. Abnormalities in the epigenome have been identified in many diseases, providing a promising new path for drug discovery. Internationally renowned expert in the field of cancer research, Dr. Craig B. Thompson, Memorial Sloan Kettering Cancer Center, delivered the keynote address at the symposium which was chaired by Dr. Norman Wong, Resverlogix’s Chief Scientific Officer and Dr. Dominique Verhelle of Third Rock Ventures. Dr. Ewelina Kulikowski, Senior Vice President of Research & Development presented on behalf of Resverlogix. Additional speakers included: Dr. Michael Elowitz, California Institute of Technology, Dr. Keiko Ozato, National Institute of Child Health and Human Development, Dr. Roberto Pili, Indiana University School of Medicine, Dr.Patrick Trojer, Constellation Pharmaceuticals, Dr. Christopher Vakoc, Cold Spring Harbor Laboratory, Daniel Vitt, 4SC AG, and Dr. Eric Campeau, Zenith Epigenetics.
The Epigenetics: Cancer and Beyond eBriefing is posted to the Academy website. It is open to the public and can be accessed HERE.